West Palm Beach, Florida, December 2007 – The ComVest Group has acquired Southern Comfort Conversions (“Southern Comfort”). The largest vehicle converter in the United States, the Company has both strategic alliances with automobile manufacturers, particularly General Motors, and a large dealer distribution network. Through its alliance with GM, the Company has recently secured exclusive contracts to produce Special Edition Hummers and customized Cadillac Escalades. ComVest anticipates the company is well positioned for significant growth.

About Southern Comfort
Southern Comfort is a vertically integrated manufacturer and chassis converter for General Motors, Ford and Dodge. Southern Comfort is the largest automobile aftermarket up-fitter in the United States and provides specialty manufacturing services to the marine, motor home and golf industries. The Company provides a superior and unique paint job to standard vehicles off the assembly line, and creates custom lighting, proprietary ground effects and wheels, and an attractive interior finish. This customized look creates a very appealing and distinct product for dealers who are increasingly looking for differentiation as a competitive edge in the marketplace and allows dealers the opportunity to close higher margin sales. For more information please visit www.scomfort.com.

About ComVest
The ComVest Group is a leading investment firm focused on investing in middle-market companies in a debt or equity capacity. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

West Palm Beach, Fl., November 1, 2007 – ComVest’s portfolio company, Averion International Corp. (OTC:AVRO) (“Averion”), today announced that it has acquired Hesperion AG (“Hesperion”), a Swiss-based, international, full-service, clinical research organization (CRO), from its parent company, Cerep SA. The €25.0 million (approximately $36.2 million) acquisition purchase price included an upfront cash payment of €20.0 million ($29.0 million) with an additional €5.0 million (approximately $7.2 million) to be paid within thirty days through the issuance of a promissory note. With the completion of this acquisition, Averion now has 14 offices in 10 countries, a significantly strengthened presence in Europe, and has doubled its full-time employee base to approximately 400.

Averion today also announced that it has completed a senior secured debt financing, raising gross proceeds of $24.0 million to fund the acquisition through the issuance of three-year senior secured notes. The Company will also receive additional gross proceeds of $2.0 million within thirty days after the initial closing on the same terms, resulting in aggregate gross proceeds of $26 million to the Company from both closings. At such time as the additional $2.0 million in notes are purchased, the purchasers will also be issued an additional 9,600,000 shares of common stock. Collins Stewart LLC and Commonwealth Associates acted as co-placement agents and Jefferies & Company, Inc. acted as co-advisors for the transaction.

Philip T. Lavin, PhD, formerly Averion’s Chief Executive Officer, has been named to the newly created position of Executive Chairman. Markus H. Weissbach, MD, PhD, Hesperion’s CEO, has been appointed CEO of Averion and will relocate to the Company’s U.S. headquarters. Dr. Weissbach brings to Averion more than 18 years of clinical research management experience in the pharmaceutical industry. Chris Codeanne remains in his current capacity as Averion’s Chief Financial Officer. Averion will continue to be headquartered in Southborough, Massachusetts with its European base of operations in Basel, Switzerland.

“The acquisition of Hesperion, a high quality European CRO, represents an ideal strategic fit with Averion’s U.S. centric business and approximately doubles the size of our Company. Both companies bring extensive long-term client relationships to the combined organization and have each been independently experiencing impressive organic growth. The combination creates a mid-size global CRO capable of managing complex larger global clinical trials for its clients,” said Michael Falk, Chairman of Averion’s Board of Directors.

“Current CRO industry trends indicate a growing need for the ability to perform larger, full-service global trials. With this transaction, we enhance our competitive position by doubling the size of our operations and broadening our client base,” said Dr. Lavin. “We have the capabilities to span the CRO lifecycle from first-in-man clinical trials through marketing authorization and into post-market surveillance and reimbursement. Averion now has the operational capacity necessary to compete for global clinical programs.”

“Hesperion has outperformed the CRO sector, achieving more than 20% annual growth over the last three years,” said Dr. Weissbach. “With this transaction, the new Averion will be more competitive in the CRO market. We share a commitment to provide critical thinking and quality processes that are necessary for the development of strong customer partnerships. We believe the acquisition will allow us to expand the depth and breadth of quality services we provide to our clients.”

About Hesperion

Founded in 1996, Hesperion has extensive experience and expertise in cardiology and oncology. Hesperion has focused on establishing clinical development partnerships with medical device, biotech and pharmaceutical companies and has employed clinical research professionals worldwide with expertise in medical and regulatory affairs, clinical operations, data management and statistics. Hesperion has conducted more than 220 projects involving 41,000 subjects in 40 countries for more than 110 clients, and it has been successfully audited by EMEA and FDA for its work on the pivotal studies of Tracleer®, the breakthrough orphan treatment for pulmonary arterial hypertension developed by Actelion Ltd.

About Averion International Corp.

Averion International Corp. is a full service clinical research organization (CRO) that provides clinical research services to the pharmaceutical, biotechnology and medical device/diagnostic industries. The Company has a therapeutic focus in oncology, medical devices, dermatology and nephrology. Averion’s core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including: oncology, medical devices, dermatology, and nephrology.

Averion is headquartered in Southborough, Mass. with European operations based in Basel, Switzerland. Averion has additional U.S. offices in California, Maryland and New York; and additional European offices in Austria, France, Germany, The Netherlands, Poland, Russia, and the United Kingdom; a location in Israel; and partnerships in Hungary, India and South America. For more information, visit www.averionintl.com.

About Cerep

Cerep’s mission is to provide pharmaceutical companies with high quality services in drug discovery and drug development. Cerep provides solutions allowing faster and cost effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep has developed a unique know-how based on technologies of in vitro screening and profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties.

Cerep’s technologies benefit more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.

Over the past years, Cerep also developed a pipeline of drug candidates which includes collaborative products developed with Sanofi-Aventis and Bristol-Myers Squibb, as well as proprietary compounds (including one compound in phase I/II clinical trial in the field of cancer). These programs and associated compounds are either partnered or being licensed-out.

About ComVest
The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

Included in this release are “forward-looking statements.” Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company’s actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is not under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

West Palm Beach, Florida, October 2007 – The ComVest Group, through its Control Fund, ComVest Investment Partners III, LP, has acquired Hi-Way Equipment Company (“Hi-Way”) for $17.25 million. ComVest has also acquired the plant and inventory from which Hi-Way conducts its operations.

About Hi-Way
Hi-Way is based in Houston, Texas, and is a multi-line dealer and distributor for heavy equipment manufacturers. The company sells, rents, and services telescopic boom excavators, front-end loaders, paving and asphalt machines, pipe handlers, street sweeping equipment, and various ancillary parts and attachments. The company services private contractors and governmental entities in the highway construction, drainage improvement, and commercial and industrial sectors. For more information, please visit www.hi-wayequipment.com.

About ComVest
The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

ATLANTA–Sept. 5, 2007–CDC Software, a wholly owned subsidiary of CDC Corporation (NASDAQ: CHINA) and a provider of industry-specific enterprise software applications and business services, announced today that it has entered into a definitive agreement to acquire a portfolio company of ComVest, Milwaukee-based Catalyst International, a leading provider of supply chain execution solutions and services. With approximate annual revenues of (U.S.) $35 million, the acquisition of Catalyst is expected to be immediately accretive to CDC Software upon completion of the acquisition.

Catalyst’s software solutions and services are highly complementary to CDC Software’s IMI Supply Chain product line and the company’s CDC Global Services operations. The IMI suite of supply chain solutions supports demand-driven fulfillment in multi-company, multi-site and multi-channel environments. After completion of the acquisition, the Catalyst SAP practice business segment is expected to be merged into CDC Global Services, which provides consulting and outsourcing services across a variety of technologies and industries.

“This acquisition will expand our global supply chain offerings and base of blue-chip customers, and at the same time, strengthen our CDC Global Services offerings by adding significant expertise and resources in large-scale supply chain execution,” said Eric Musser, CEO of CDC Software. “We are also excited about the advanced architecture of CatalystConnect, an event-driven, rules-based workflow platform that will serve as an integration backbone in the future for CDC Software’s applications. The Catalyst International SAP logistics consulting practice will extend our strategy of building services practices across key areas of the ERP application space. We look forward to a continuing strong relationship with companies such as SAP.”

“CDC Software will bring the depth of its global resources focused on technology innovation, application development, and professional services, as well as sales, marketing and customer service,” said Michael Eleftheriou, president and CEO of Catalyst International. “They also bring a track record of investments in acquired products and extremely high levels of customer satisfaction. This big step in our evolution will be very beneficial to Catalyst and our customers.”

Catalyst provides a broad range of integrated, open standards-based solutions that service key areas of complex supply chains and distribution networks. The solutions can operate as standalone modules that can readily integrate into an enterprise’s existing applications. Key functionality in the Catalyst suite includes warehouse management, transportation management, dynamic route planning, slotting, labor management, cross dock planning, and yard management.

Complementing the CDC Software IMI blue-chip customers that include Ahlsell, Campbell Soup, Canadian Tire, Frito Lay, GE Plastics, JM Smuckers, Sherwin Williams and Starbucks, the customers of Catalyst International include industry leaders such as: Aldo Group, Centocor, The Container Store, Fuji, General Motors, Homebase, Jarden, Jim Beam, Legrand Group, Office Max, Reebok, Shanghai General Motors, Solectron and Symbol/Motorola.

The completion of the acquisition is subject to the satisfaction of a number of customary conditions precedent. CDC Software currently anticipates that the transaction will be completed by the end of September 2007.

About CDC Software

CDC Software, The Customer-Driven Company(TM), is a provider of enterprise software applications designed to help organizations deliver a superior customer experience while increasing efficiencies and profitability. CDC Software’s product suite includes: CDC Factory (manufacturing operations management), Ross ERP (enterprise resource planning) and SCM (supply chain management), IMI warehouse management and order management, Pivotal CRM and Saratoga CRM (customer relationship management), Respond (customer complaint and feedback management), c360 CRM add-on products, industry solutions and development tools for the Microsoft Dynamics CRM platform, Platinum HRM (human resources) and business analytics solutions.

These industry-specific solutions are used by more than 6,000 customers worldwide within the manufacturing, financial services, health care, home building, real estate, and wholesale and retail distribution industries. The company completes its offerings with a full continuum of services that span the life cycle of technology and software applications, including implementation, project consulting, outsourced business services, application management and offshore development. CDC Software is the enterprise software unit of CDC Corporation (NASDAQ: CHINA) and is ranked number 12 on the Manufacturing Business Technology 2007 Global 100 List of Enterprise and Supply Chain Management Application vendors. For more information, please visit www.cdcsoftware.com.

About CDC Corporation

The CDC family of companies includes CDC Software focused on enterprise software applications and services, CDC Mobile focused on mobile applications, CDC Games focused on online games, and China.com focused on portals for the greater China markets. For more information about CDC Corporation (NASDAQ: CHINA), please visit www.cdccorporation.net.

About Catalyst

Catalyst International, Inc. is a software and services company specializing in building and implementing business solutions for the enterprises’ needs in supply chain execution, planning, and management. These solutions are based on its comprehensive, open architecture, integrated suite of software, which offers Warehouse Management WMS, Yard Management YMS, Labor Management LMS, and Transportation Management TMS, as well as Slotting, RFID, and Inventory Optimization; on its Best-Of-Breed, and SAP services practice. Catalyst’s solutions cater to the enterprises’ complex distribution networks in the retail, manufacturing, life sciences, process, and consumer packaged good sectors; and parts distribution for the automotive, aerospace, and electronics. Headquartered in Milwaukee, Wisconsin, Catalyst has its EMEA headquarters in London, and is represented in Italy, Mexico, Latin America, Canada, China, and India, and implements programs for clients around the world.

About ComVest
The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through the firm’s extensive financial resources and broad network of industry experts, it is able to offer portfolio companies total financial sponsorship, critical strategic support, and business development assistance. ComVest’s focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, including statements relating to expectations that such transaction will be accretive, the expectation that the acquisition will strengthen the supply chain and services portfolio, the complementary nature of Catalyst solutions with IMI, our statements regarding our strategy, value and market positions, our statements regarding leadership and management, our statements regarding the expected benefit of the acquisition and other statements that are not historical fact, the achievement of which involve risks, uncertainties and assumptions. These statements are based on management’s current expectations and are subject to risks and uncertainties and changes in circumstances. There are important factors that could cause actual results to differ materially from those anticipated in the forward looking statements including, among others: the conditions of the supply chain solutions industry; the ability of Catalyst solutions to address industry-specific requirements; development of new functionalities which would allow other companies to compete more effectively and changes in the type of information required to compete in the supply chain execution industry. Further information on risks or other factors that could cause results to differ is detailed in filings or submissions with the United States Securities and Exchange Commission made by CDC Corporation in its Annual Report for the year ended December 31, 2006 on Form 20-F filed on July 2, 2007. All forward-looking statements included in this press release are based upon information available to management as of the date of the press release, and you are cautioned not to place undue reliance on any forward looking statements which speak only as of the date of this press release. The company assumes no obligation to update or alter the forward looking statements whether as a result of new information, future events or otherwise.

West Palm Beach, Fl, May 2007- The ComVest Group announced that its portfolio company, CorVu Corporation, an innovative provider of Business Intelligence and Performance Management software solutions, has been acquired by Rocket Software, Inc. in a transaction valued at $24.5 million.

About CorVu Corporation
A pioneer in Balanced Scorecard software and reporting dashboards, CorVu has been a leader in automating business performance management practices for more than 10 years. CorVu’s innovative software uniquely combines performance metrics, initiatives, budgeting and planning, risk management, and reporting in a single application. The CorVu solutions are purpose-built applications that are easy to use, scalable, and rapidly deployable. For more information about CorVu, please visit www.corvu.com.

About Rocket Software, Inc.
Rocket Software is a global software development firm that builds Enterprise Infrastructure products for the world’s leading OEMs, networks and software companies. The company’s current lines of business complement and extend strategic OEM offerings in the areas of business intelligence, enterprise and mobile security, relational databases, mobile and wireless computing, and operational support systems (OSS). Rocket’s current OEM relationships and technology partners include IBM, EMC, HP, RSA Security, Microsoft, Nortel, and Motorola. Rocket Software is based in Newton, Massachusetts. For more information, visit www.rocketsoftware.com.

About ComVest
The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

WEST PALM BEACH, FL–Apr 25, 2007 — ComVest Group Holdings, LLC announced today that it has entered into a definitive agreement with EVCI Career Colleges Holding Corp. (NasdaqCM:EVCI – News) and participating management of EVCI that will provide gross proceeds to EVCI of $10,100,000 and the ability to secure letters of credit of up to $6,700,000 (the “Financing”). The agreement with ComVest provides for a closing by May 24, 2007, with no conditions other than the wiring of funds and the issuance of the securities. EVCI will restructure its bank debt (the “April 2007 Debt Restructuring”) at the same time as the Financing is closed.

EVCI also announced that Robert F. Kennedy Jr., the son of the late Senator Robert F. Kennedy, and a professor at Pace School of Law has joined the EVCI board of directors to head up a new Educational Oversight Committee.

Michael Falk, Chairman of the ComVest Group, stated, “ComVest’s extensive due diligence over the last several months has convinced us that EVCI Career Colleges are high quality institutions run with integrity. We are pleased that the EVCI board has taken the steps to institute an Educational Oversight Committee and appointed Bobby Kennedy to lead it.”

Dr. John J. McGrath, CEO and President of EVCI, stated, “I am pleased to announce to our investors that the financing transaction provides EVCI with the capital resources to enhance the academic, administrative and financial integrity of our colleges. This financing is great news for our students, faculty and college administration at Technical Career Institutes, Interboro Institute and the Pennsylvania School of Business.”

Dr. Arol I. Buntzman, Chairman of EVCI, commented, “I am absolutely delighted that Bobby Kennedy has joined EVCI’s Board of Directors. His integrity and commitment to economically disadvantaged minorities is a perfect fit for our vision and mission.”

Bobby Kennedy commented, “More than 50% of the students that start in the New York City public schools do not graduate from high school. Technical Career Institutes and Interboro Institute are a life-raft to thousands of New Yorkers who are most vulnerable. EVCI’s colleges lift many economically disadvantaged minorities from hopelessness to harbors of hope and opportunity. I am thrilled with the idealism, pragmatism and professionalism of EVCI’s executive leadership. I am also very impressed with the faculty and administration at the colleges, and their embracing commitment to providing higher education opportunity to those most in need.”

Dr. Buntzman reported that Inder Tallur, and Brian Fluck, partners of ComVest, will join the EVCI board upon the closing of the Financing. Mr. Kennedy replaced Elie Housman, and Messrs. Tallur and Fluck will replace Royce Flippin and Richard Goldenberg as directors. None of the departing directors are leaving EVCI over any disagreement with management or other Board member.

Brian Fluck brings nearly 30 years of executive financial and operational leadership experience to EVCI, formerly serving as Chief Financial Officer of ATT Universal Services and Chairman of the Board of the independent bank through which this business was conducted. Mr. Fluck more recently was President and board member of several CNL Financial Group, Inc. companies, one of which was acquired by Lehman Brothers. Mr. Fluck brings strong executive management and board of directors experience to the EVCI board. Mr. Fluck is scheduled to join ComVest Investment Partners III as a full-time operating partner at about the time of the closing of this transaction.

Inder Tallur brings 12 years of investment experience in various roles at ComVest, including researching the educational sector during his tenure as Director of Research at Commonwealth Associates, an affiliate of the ComVest Group.

The Financing has been structured so that it will not result in a change of control of EVCI until such time as all required preapprovals have been obtained under applicable rules and regulations of the governmental agencies regulating the operation of EVCI’s colleges and the non-governmental entities that accredit our colleges.

The terms of the Financing, including the agreements with EVCI management, have been approved by EVCI’s Board of Directors based upon the unanimous recommendations of a Special Committee of EVCI’s Board that was formed on February 2, 2007, and consists of EVCI’s four independent directors. Seidman & Co., Inc., financial advisor to the Special Committee, has rendered an opinion to the Special Committee that concludes the Financing is fair to EVCI’s stockholders.

At the Closing, EVCI will issue 2,525,234 shares of common stock at $0.54 per share (the “Shares”), $8,736,374 in face amount of 12% secured convertible notes, which will be convertible into EVCI’s common stock if the Notes are not repaid within 12 months, at $0.60 per share, subject to adjustment, and will mature in 36 months (the “Notes”).

The net proceeds of approximately $8,000,000 from issuance of the Notes and Shares, after payment of transaction fees estimated to be approximately $2.0 million, will be used to repay EVCI’s term loan bank debt. Under the restructuring of the bank agreement, EVCI will have access to $11.0 million of future borrowing using a $5.0 million revolver and by increasing the term loan to $6.0 million.

ComVest will be required to assist EVCI in obtaining a one year letter of credit of up to $6.7 million in favor of the U.S. Department of Education and, if required, the New York State Education Department or its designee. ComVest will either provide a corporate guaranty to the provider of the letter of credit or procure the letter of credit. For agreeing to assist EVCI, ComVest will receive a cash fee of $234,500 that will accrue until the senior debt is paid. To the extent EVCI is required to provide the letter of credit, EVCI will accrue a monthly fee of 1.37% of the face amount of the outstanding letter of credit. The letter of credit would be used to satisfy financial responsibility standards of regulators of our schools. In connection with issuance of the Notes and agreeing to assist EVCI to obtain the letter of credit, three year warrants to purchase up to 27,500,000 shares of EVCI’s common stock at $0.54 per share, subject to adjustment (the “Warrants”),will also be issued to ComVest.

The Warrants and most of the Notes will not be exercisable and convertible unless EVCI’s stockholders approve an increase in EVCI’s authorized common stock. If stockholders do not approve the Notes become due and payable, subject to an intercreditor agreement with EVCI’s bank that subordinates the Notes to the bank’s senior debt.

Dr. Arol I. Buntzman, EVCI’s chairman, Dr. John J. McGrath, EVCI’s chief executive officer and president, Joseph D. Alperin, EVCI’s general counsel and vice president for corporate affairs and Stephen K. Schwartz, EVCI’s vice president of operations (collectively “Participating Management”) have agreed to participate in the Financing. Drs. Buntzman and McGrath and Mr. Alperin entered into amendments to their employment agreements and Mr. Schwartz entered into a new employment agreement.

Participating Management will invest $1,000,000 on a pari passu basis with ComVest Investment Partners III, L.P., as follows: Dr. Arol I. Buntzman, $500,000; Dr. John J. McGrath, $250,000; Joseph D. Alperin, $125,000 and Stephen Schwartz, $125,000.

The employment agreements with Participating Management provide for:

— the surrender of options to purchase 916,484 shares that are
exercisable at $1.00 per share.
— reductions in salary aggregating $350,000 per annum.
— a cash bonus pool of 10% of EBITDA (as defined), subject to a cap of
100% of their salaries.
— a grant of options on April 24, 2007 to purchase 2,157,113 shares of
EVCI’s common stock at $0.583 per share.
— a grant of options on April 24, 2007, subject to stockholder approval,
to purchase 4,376,559 shares of EVCI’s common stock at $0.54 per share.

Additional information regarding the terms of the Financing will be disclosed in EVCI’s form 10-K for its year ended December 31, 2006 that it plans to file with the SEC by April 27, 2007.

About EVCI Career Colleges Holding Corp.
EVCI is the holding company for Interboro Institute, Technical Career Institutes and the Pennsylvania School of Business.

Founded in 1888, Interboro offers degree programs leading to the Associate in Occupational Studies degree and Associate in Applied Sciences degree. Its programs include accounting, business management, ophthalmic dispensing, paralegal studies, office technologies and security services and management. Interboro has a main campus in mid-town Manhattan, an extension center in each of Flushing, New York and in the Washington Heights section of Manhattan, New York. EVCI acquired Interboro in January 2000.

Founded in 1909, TCI offers two-year associate degree and certificate programs. With an emphasis on technology, TCI offers programs within three major divisions: business and new media technology, computer and electronics technology and climate control technology. TCI’s main campus is on 31st Street diagonally across from Penn Station, and is supported by a nearby annex facility. EVCI acquired TCI in September 2005.

PSB is authorized to offer two Associate in Specialized Business degree programs and two diploma programs in information technology as well as three recently authorized business diploma programs. As permitted by the Pennsylvania State Education Department, after six months of teaching the three business diploma programs, PSB plans to seek authorization to award the Associate in Special Business degree for those programs. PSB relocated to downtown Allentown, Pennsylvania. EVCI acquired PSB in January 2005.

For more information on EVCI, please visit www.evcinc.com.

About ComVest
The ComVest Group is a Leading Private Equity Firm focused on investing in small and mico-cap companies. Since 1988, ComVest has invested more than $2 billion of capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, please visit www.comvest.com.

West Palm Beach, Florida, December 8, 2006 – The ComVest Group announced the $90 million initial public offerings of its portfolio company, Allegiant Travel Company (NASDAQ: ALGT). Five million shares of common stock were priced at $18.00 per share and the common stock will trade on the NASDAQ Stock Market under the symbol “ALGT”. Merrill Lynch & Co. acted as sole book-running manager for the offering. Bear Stearns & Co. Inc. and Raymond James served as co-managers. Allegiant has granted the underwriters a 30-day option to purchase up to an additional 750,000 of common stock to cover overallotments, if any.

Las Vegas-based Allegiant is a leisure travel company focused on linking travelers in small cities to world-class leisure destinations such as Las Vegas, Nev., Orlando, Fla. and Tampa/St. Petersburg, Fla. Allegiant operates a low-cost passenger airline marketed to leisure travelers in small cities, allowing Allegiant to sell air travel both on a stand-alone basis and bundled with hotel rooms, rental cars and other travel related services.

Proceeds from the offering are expected to be approximately $82.3 million or $94.9 million if the underwriters exercise their overallotment option in full, after deducting the underwriting discounts and commission and the estimated offering expenses. The proceeds from the offering will be used to retire certain indebtedness, purchase additional aircraft consistent with Allegiant’s growth strategy and acquisition criteria, and for general corporate purposes, including working capital.

About Allegiant
From America’s favorite small cities to world-class destinations, Allegiant Air makes leisure travel affordable and convenient. With low-low fares, nonstop, all-jet service and premier travel partners, Allegiant Air provides a complete travel experience with great value and without all the hassle. Allegiant Air was founded in 1997 and is certificated by the U.S. Department of Transportation (DOT) as a “Scheduled Air Carrier” with authority to fly scheduled and charter airline operations throughout the U.S. The Company also has authority for charter service to Canada and Mexico.

About ComVest
The ComVest Group is a Leading Private Equity Firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of equity capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Their focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

Included in this release are “forward-looking statements.” Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company’s actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is not under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

West Palm Beach, FL — Medical device maker AngioDynamics Inc. (NASDAQ: ANGO) said Tuesday it is purchasing one of The ComVest Group’s portfolio companies, oncology products maker Rita Medical Systems Inc. (NASDAQ: RITA) for about $220 million, plus approximately $3.3 million in assumed debt.
Rita shareholders will receive cash and stock totaling $4.70 per share, based on the assumption that Angiodynamics’ average 10-day closing stock price three days prior to shareholder meetings will range between $18.18 and $27.29 per share. Following the merger, Rita shareholders will own a 34.5 percent stake in the combined company. The purchase price represents a 19 percent premium to Rita’s Monday closing stock price of $3.95 on the Nasdaq, where the stock has ranged between $3.06 and $4.65 over the past year. The stock jumped 43 cents, or 10.9 percent, to $4.38 on the news, nearing its 52-week peak of $4.65.

Based in Fremont, Calif., Rita makes a system consisting of a radiofrequency energy generator and disposable accessories that is used in minimally invasive or laparoscopic procedures to superheat and kill tumors. The system is approved to treat liver cancer and is sold in Asia, Europe and the U.S. The company, which has about 221 workers, posted sales of $46.4 million in 2005.

AngioDynamics said the transaction, excluding one-time charges, is expected to be neutral to fiscal 2007 earnings and will add about 5 cents per share to fiscal 2008 net income. AngioDynamics’ board will include three Rita members after the transaction is complete.

The deal is seen closing by the end of the first quarter of 2007, subject to regulatory review, shareholder approval and other customary closing conditions. Angiodynamics expects the merger to eliminate $9 million of annual costs related to corporate and tradeshow expenses.

“Rita’s talented 33-person U.S. sales force targets the same customer base as does AngioDynamics’ 52-person U.S. sales force and the companies have virtually no product overlap,” said Eamonn P. Hobbs, president and CEO of AngioDynamics. “Rita has a very strong position in vascular access ports, which are an ideal sales fit with our Morpheus CT PICC and the vascular access port technology we purchased from Medron last May.”

Angiodynamics said the current Rita sales organization will remain intact after the merger closes. AngioDynamics’ sales force will take on responsibility for Rita’s specialty access catheter business, and leverage Rita’s 10-person direct sales force in Britain, Germany and France to sell AngioDynamics’ products.

Angiodynamics, which makes medical devices to treat non-cardiac vascular diseases, has about 300 employees and recorded 2006 sales of $78.4 million.

About Angiodynamics
AngioDynamics, Inc. engages in the design, development, manufacture, and marketing of therapeutic and diagnostic devices to treat peripheral vascular disease and other noncoronary diseases in the United States, Europe, and Japan. Its products include angiographic products and accessories, including angiographic catheters, and uncoated, Teflon-coated, and hydrophilic-coated guidewires to support its angiographic catheter line; dialysis products, including catheters that provide short- and long-term vascular access for dialysis patients; vascular access products; and venous products used in endovascular laser procedures to treat venous insufficiency of the great saphenous vein and Sotradecol, a sclerosing drug. The company also offers thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs that dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; percutaneous transluminal angioplasty dilation balloon catheters; intra-vascular devices to measure blood flow in dialysis access sites during an access site clearing procedure; and drainage catheters. The company’s products are used by interventional radiologists and other physicians for the minimally invasive, image-guided procedures. For more information on Angiodynamics, visit www.angiodynamics.com.

About RITA Medical Systems
RITA Medical Systems, Inc., a diversified medical device oncology company, engages in the development, manufacture, and marketing of products that use radiofrequency energy to treat patients with cancerous or benign tumors. It offers radiofrequency ablation systems (RFA) for treating cancerous tumors, as well as percutaneous vascular ports and specialty access catheters (SAC). Its SAC products include implantable infusion ports for the delivery of systemic chemotherapy, implantable ports, hemodialysis catheters, needle infusion sets, peripherally inserted central venous catheters, other accessories used in vascular procedures, tunneled central venous catheters, safety needles, PICC lines, dialysis catheters, and specialty catheters for the stem cell transplant procedure. It also distributes a radiofrequency product, the HABIB 4X resection device, which is designed to limit blood loss in surgical resection procedures. The RFA products include disposable devices and generators that are used for the liver cancer and the bone cancer market. Its customers include surgical oncologists, hepatobiliary surgeons, liver transplant surgeons, laparoscopists, and interventional radiologists, as well as patient referral sources, including colorectal surgeons, radiation oncologists, and medical oncologists. It markets its products through a direct sales force and distributors in the United States, and through distribution partners in Europe and Asia. For more information on RITA Medical, visit www.ritamedical.com.

About ComVest
The ComVest Group is a Leading Private Equity Firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of equity capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, we are able to offer our companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

West Palm Beach, Florida, October 20, 2006 – The ComVest Group has acquired Zomax Inc. (”Zomax”) in an all cash transaction valued at $72 million, or approximately $2.09 per share.

“ComVest has experience as an investor in the supply-chain management industry and we are pleased that they have chosen to further their commitment in the industry through Zomax,” said Anthony Angelini, president and CEO of Zomax. “ComVest’s knowledge of the supply-chain and logistics industry will be an asset to Zomax as a private company. Through this transaction we are confident that Zomax will be able to continue to provide its customers with the superior products and services they have come to expect from the Company, and over the long-term, reach its true market potential.”

Zomax stockholders will receive $2.09 in cash for each share of Zomax common stock they hold.

“Our Board believes this transaction is in the best interest of the Company and our shareholders,” added Howard Liszt, chairman of Zomax. “ComVest has experience in our market and we feel that this is the best course of action for the Company to take at this time…”

“This transaction represents our continuing commitment to the supply chain solutions space which began with our investment in Inoveris,” said Robert Priddy, a Managing Partner of ComVest. “Zomax’s impressive customer base and understanding of the value of customer service coupled with its expertise in the supply chain solutions market should allow us to expand the market share of both companies. We look forward to working with Zomax to reach our mutual goals.”

About Zomax

Zomax helps companies more efficiently bring their products and content to market worldwide. Our comprehensive program management approach helps companies develop, manage and improve their rapidly changing product and program supply chains. Zomax’s solutions leverage a modular suite of supply chain services that include project management, data management, customer contact and e-commerce services, sourcing management, CD/DVD production, assembly and kitting services, JIT physical and electronic fulfillment, and returns management. Founded in 1993, Zomax currently operates 8 facilities across the United States, Canada, Mexico and Ireland. For more information on Zomax, visit www.zomax.com or call (866) 553-9393.

About ComVest

The ComVest Group is a Leading Private Equity Firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of equity capital in over 200 public and private companies worldwide. Through their extensive financial resources and broad network of industry experts, they are able to offer their companies total financial sponsorship, critical strategic support, and business development assistance. Our focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.

About Inoveris
Inoveris enables companies to streamline the process of delivering products and information to market by providing technology driven supply chain solutions that reduce costs and increase efficiencies. Acting as an extension of a company’s infrastructure, Inoveris provides a single-source solution to execute all supply chain needs. From sourcing, to kitting and assembly, to physical and electronic distribution, to complex inventory management, Inoveris delivers competitive advantage at a time when supply chain efficiency is critical to a company’s success. For additional information, please visit www.inoveris.com.

West Palm Beach, Florida, October 20, 2006 – The ComVest Group announced that it has completed the purchase of Stonepath Logistics International Services, Inc. (“SLIS”), a division of The Stonepath Group (AMEX: STG), for aggregate consideration of $17.9 million. ComVest expects to finalize the purchase of the Stonepath Logistics (Germany) GmbH unit, for a proposed combined purchase price of $18 million. SLIS, based in Seattle, Washington, is a logistics business that provides international air and ocean logistics services.

The ComVest Group, through its private equity control fund, ComVest Investment Partners II LLC, has partnered with Jason F. Totah, who served as The Stonepath Group’s previous Chief Executive Officer, to effect the buyout of these division(s). The investment vehicle formed to consummate the transaction is JTM Acquisition Corporation (“JTM”), and will be controlled by ComVest. Jason Totah will continue to manage the company, which will operate under the new name of Global Transportation Service Inc.

About Stonepath Group (Amex: STG)

Stonepath is a global, third-party logistics organization providing a full range of transportation and distribution solutions to multinational and local businesses including a diverse client mix of retail leaders, automotive and technology concerns, government agencies, and defense contractors. For more information on Stonepath, visit www.stonepath.com.

About The ComVest Group

The ComVest Group is a leading Private Equity firm focused on investing in middle-market companies. Since 1988 ComVest has invested more than $2 billion of equity capital in over 200 public and private companies worldwide. Through our extensive financial resources and broad network of industry experts, they are able to offer their companies total financial sponsorship, critical strategic support, and business development assistance. Their focus is centered on building industry leading companies and creating long term value for equity holders. For more information on ComVest, visit www.comvest.com.